BioCentury | Feb 10, 2020
Product Development

vTv’s potential first-in-class therapy heading for Phase III after clearing Type I diabetes hurdle

Based on the 52% bump that vTv’s shares received on Monday, investors believe new data from a Phase II trial of the company’s glucokinase activator to treat Type I diabetes could portend further success in...
BC Extra | Nov 13, 2019
Clinical News

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by the limitations of previous compounds. Yet...
BC Innovations | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BioCentury | May 17, 2019
Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
BC Week In Review | Feb 8, 2019
Clinical News

Hua starts U.S. Phase I trial of diabetes candidate

Hua Medicine Ltd. (HKEX:2552) began a Phase I trial of its dorzagliatin (sinogliatin, HMS5552, RO5305552) in combination with Januvia sitagliptin in patients with Type II diabetes. The open-label, U.S. trial will evaluate the pharmacokinetic and...
BioCentury | Sep 15, 2018
Finance

Hua’s institutional advantage

The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO tempered participation by retail investors, which could help keep the Shanghai diabetes company’s share price steady amidst...
BC Week In Review | Sep 14, 2018
Financial News

Hua raises $110.5M in HK IPO, trades flat on first day

Hua Medicine Ltd. (HKSE:2552) shares ended the day unchanged at HK$8.28 in the company's first day of trading Sept. 14. The diabetes play raised HK$867 million ($110.5 million) in an IPO through the sale of...
BC Extra | Sep 14, 2018
Financial News

Hua trades flat in Hong Kong debut

Hua Medicine Ltd. (HKSE:2552) shares ended the day unchanged at HK$8.28 in the company's first day of trading Friday. The diabetes play raised HK$867 million ($110.5 million) in an IPO through the sale of 104.8...
BC Extra | Sep 13, 2018
Financial News

Hua raises $110M in Hong Kong IPO

Diabetes company Hua Medicine Ltd. (HKSE:2552) raised HK$867 million ($110.5 million) in an IPO through the sale of 104.8 million shares at HK$8.28. EVP and CFO George Lin said the offering, which priced at the...
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
Items per page:
1 - 10 of 108